Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Becton Dickinson ( (BDX) ) has provided an announcement.
On January 30, 2026, Becton, Dickinson and Company filed a Certificate of Designation in New Jersey to create a new Series D Junior Participating Redeemable Preferred Stock, and on February 2, 2026, it entered into exchange agreements with two internal deferral plan trusts to swap portions of their BD common stock holdings for 27.5159 shares of this new preferred stock. The move is structured to prevent those trusts from receiving shares of Augusta SpinCo Corporation in BD’s planned distribution of SpinCo common stock ahead of SpinCo’s Reverse Morris Trust combination with Waters Corporation, with the preferred shares designed to be redeemable back into BD common stock, thereby fine-tuning shareholder treatment and capital structure as the separation and merger of BD’s Biosciences and Diagnostic Solutions business proceed.
The most recent analyst rating on (BDX) stock is a Buy with a $233.00 price target. To see the full list of analyst forecasts on Becton Dickinson stock, see the BDX Stock Forecast page.
Spark’s Take on BDX Stock
According to Spark, TipRanks’ AI Analyst, BDX is a Neutral.
The score is driven primarily by stable financial performance (healthy margins, improving leverage, and strong cash generation) and a generally positive—but cautious—FY26 earnings outlook with clear margin and cost actions. This is tempered by a neutral technical picture in the near term and a relatively high valuation (P/E 34.72) that reduces upside if growth slows under the cited headwinds.
To see Spark’s full report on BDX stock, click here.
More about Becton Dickinson
Becton, Dickinson and Company (BD) is a global medical technology company operating in the biosciences and diagnostic solutions markets, where it provides instruments, reagents and systems used in clinical laboratories, research settings and healthcare facilities worldwide.
Average Trading Volume: 2,130,639
Technical Sentiment Signal: Buy
Current Market Cap: $59.22B
For a thorough assessment of BDX stock, go to TipRanks’ Stock Analysis page.